AIM Vaccine Valuation

Is 6660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6660's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6660?

Key metric: As 6660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6660. This is calculated by dividing 6660's market cap by their current revenue.
What is 6660's PS Ratio?
PS Ratio	6.2x
Sales	CN¥1.18b
Market Cap	CN¥7.40b

6660 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.6x
Enterprise Value/EBITDA	-5.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6660's PS Ratio compare to its peers?

The above table shows the PS ratio for 6660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14.7x
2696 Shanghai Henlius Biotech	1.8x	10.1%	HK$11.0b
1952 Everest Medicines	27x	37.2%	HK$12.1b
6185 CanSino Biologics	8.3x	33.3%	HK$11.2b
2157 Lepu Biopharma	21.8x	65.6%	HK$4.8b
6660 AIM Vaccine	6.2x	n/a	HK$7.9b

Price-To-Sales vs Peers: 6660 is good value based on its Price-To-Sales Ratio (6.2x) compared to the peer average (14.7x).

Price to Sales Ratio vs Industry

How does 6660's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
6826 Shanghai Haohai Biological Technology	2.1x	11.8%	US$1.79b
1530 3SBio	1.4x	9.3%	US$1.67b
2696 Shanghai Henlius Biotech	1.8x	10.1%	US$1.41b
775 CK Life Sciences Int'l. (Holdings)	0.8x	n/a	US$549.41m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6660 is good value based on its Price-To-Sales Ratio (6.2x) compared to the Hong Kong Biotechs industry average (11.9x).

Price to Sales Ratio vs Fair Ratio

What is 6660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6660's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

3SBio

HK$13.0b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.52

-4.3%

-26.2%

China Shineway Pharmaceutical Group

HK$6.1b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.13

-3.3%

n/a

Innovent Biologics

HK$60.6b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$37.00

-0.5%

-15.4%